Graft Polymer (UK) PLC (LSE:GPL) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about a research agreement with the University of Nottingham and Dr Madeleine King, focusing on assessing how the company's compounds could promote empathy, an essential factor in healing from trauma. This research aims to advance Graft Polymer's novel chemical entity (NCE) program, helping Graft Polymer accelerate toward clinical trials. Tennyson explained that PTSD affects over 13 million Americans and a combined total of 20 million people across the UK and key EU economies. He highlighted the company’s innovative approach, which targets the serotonin, dopamine, and noradrenaline receptors crucial to trauma processing. On the University of Nottingham collaboration, Tennyson noted, “This will enable us to take that research forward because it will help us select a lead series.” He emphasised the importance of bringing more effective treatments to PTSD patients as quickly as possible. To stay updated on Graft Polymer's progress, visit Proactive's YouTube channel, and don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #PTSDResearch #BiotechInnovations #GraftPolymer #MentalHealth #PostTraumaticStressDisorder #Therapeutics #Serotonin #Dopamine #Neuroscience #Eurofins #UniversityOfNottingham #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews